Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. Results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results